These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35202771)

  • 1. Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    He K; Li J; Xi W; Ge J; Sun J; Jing Z
    Diabetes Res Clin Pract; 2022 Mar; 185():109791. PubMed ID: 35202771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Sun L; Deng C; Gu Y; He Y; Yang L; Shi J
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101876. PubMed ID: 35321843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Hu C; Qu T; Li L; Huang Y; Liu H; Rao C
    Afr Health Sci; 2023 Jun; 23(2):416-421. PubMed ID: 38223613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhang Y; Liu X; Zhang H; Wang X
    Front Endocrinol (Lausanne); 2022; 13():836455. PubMed ID: 35282455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD.
    Hadi A; Mohammadi H; Miraghajani M; Ghaedi E
    Crit Rev Food Sci Nutr; 2019; 59(15):2494-2505. PubMed ID: 29584449
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Nigella sativa in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Tang G; Zhang L; Tao J; Wei Z
    Phytother Res; 2021 Aug; 35(8):4183-4193. PubMed ID: 33728708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Loman BR; Hernández-Saavedra D; An R; Rector RS
    Nutr Rev; 2018 Nov; 76(11):822-839. PubMed ID: 30113661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Mahmoodi M; Mosallanezhad Z; Jalali R; Imanieh MH; Moosavian SP
    Complement Ther Med; 2020 Jan; 48():102283. PubMed ID: 31987259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Guo XF; Wang C; Yang T; Li S; Li KL; Li D
    Food Funct; 2020 Sep; 11(9):7389-7399. PubMed ID: 32966467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials.
    Sun YN; Zhou Y; Chen X; Che WS; Leung SW
    Syst Rev; 2013 Nov; 2():103. PubMed ID: 24225054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Abolfathi M; Mohd-Yusof BN; Hanipah ZN; Mohd Redzwan S; Yusof LM; Khosroshahi MZ
    Complement Ther Med; 2020 Jan; 48():102273. PubMed ID: 31987257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 17. Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Tang X; Zhang H; Wang X; Yang D
    Afr Health Sci; 2022 Sep; 22(3):391-398. PubMed ID: 36910362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis.
    Hu H; Wang J; Li X; Shen L; Shi D; Meng J
    Curr Pharm Des; 2021; 27(29):3235-3243. PubMed ID: 33719959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of medicinal and food homologous substances on blood lipid and blood glucose levels and liver function in patients with nonalcoholic fatty liver disease: a systematic review of randomized controlled trials.
    Zhang Q; Jia Y; Zhang Y; Wang Y; Li X; Tian X; Han S
    Lipids Health Dis; 2023 Aug; 22(1):137. PubMed ID: 37644446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shi M; Zhang H; Wang W; Zhang X; Liu J; Wang Q; Wang Y; Zhang C; Guo X; Qiao Q; Cui C; Xu J; Wang J
    J Diabetes Complications; 2023 Oct; 37(10):108610. PubMed ID: 37722211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.